全文获取类型
收费全文 | 681篇 |
免费 | 47篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 20篇 |
妇产科学 | 5篇 |
基础医学 | 71篇 |
口腔科学 | 4篇 |
临床医学 | 44篇 |
内科学 | 139篇 |
皮肤病学 | 2篇 |
神经病学 | 106篇 |
特种医学 | 72篇 |
外科学 | 90篇 |
综合类 | 3篇 |
一般理论 | 2篇 |
预防医学 | 26篇 |
眼科学 | 2篇 |
药学 | 68篇 |
中国医学 | 7篇 |
肿瘤学 | 68篇 |
出版年
2023年 | 5篇 |
2022年 | 15篇 |
2021年 | 15篇 |
2020年 | 14篇 |
2019年 | 19篇 |
2018年 | 25篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 27篇 |
2014年 | 35篇 |
2013年 | 26篇 |
2012年 | 63篇 |
2011年 | 58篇 |
2010年 | 26篇 |
2009年 | 29篇 |
2008年 | 33篇 |
2007年 | 36篇 |
2006年 | 51篇 |
2005年 | 40篇 |
2004年 | 37篇 |
2003年 | 31篇 |
2002年 | 34篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 8篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1904年 | 1篇 |
排序方式: 共有733条查询结果,搜索用时 21 毫秒
81.
82.
83.
ABSTRACT: Two years after resection of a left parietal glioma, a 46-year-old woman underwent F-FDG and F-DOPA brain PET/CT. FDG showed left parietal hypometabolism with crossed cerebellar diaschisis. No abnormally increased FDG activity was seen. F-DOPA PET/CT scan demonstrated focal left parietal uptake. Recurrent glioma was confirmed by surgical biopsy. F-DOPA may demonstrate abnormal amino acid metabolism in evaluation of recurrence of glioma. 相似文献
84.
85.
86.
87.
Giulio Guagliumi MD FESC Davide Capodanno MD Hideyuki Ikejima MD PhD Hiram G. Bezerra MD PhD Vasile Sirbu MD Giuseppe Musumeci MD Luigi Fiocca Nikoloz Lortkipanidze MD Angelina Vassileva MD Satoko Tahara MD PhD Orazio Valsecchi MD Marco A. Costa MD PhD 《Catheterization and cardiovascular interventions》2013,81(3):510-518
88.
Sara Pilotto Antonio Rossi Tiziana Vavalà Alessandro Follador Marcello Tiseo Domenico Galetta Alessandro Morabito Massimo Di Maio Olga Martelli Orazio Caffo Pier Luigi Piovano Diego Cortinovis Nicoletta Zilembo Clelia Casartelli Giuseppe Luigi Banna Antonio Ardizzoia Maria Luisa Barzelloni Alessandra Bearz Silvia Novello 《Clinical lung cancer》2018,19(1):93-104
Background
Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study.Patients and Methods
Data of advanced NSCLC patients with uncommon EGFR mutations who received first-line first-generation EGFR-TKIs in 24 Italian Hospitals were collected. In this analysis we aimed to evaluate overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of EGFR-TKIs in NSCLC patients harboring uncommon EGFR mutations.Results
Thirty-five patients harboring uncommon EGFR mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) were included of the original 312 EGFR-mutated cases. Most of them were female (n = 20, 57.1%), former smokers (n = 23, 65.7%), with adenocarcinoma (n = 31, 88.6%). The most frequent EGFR mutations were G719X (n = 6, 17.2%) and L861Q (n = 5, 14.2%). The population presented an ORR of 25.7%, a median PFS of 5.19 months, and a median OS of 14.49 months. When stratified according to type of EGFR mutation, median OS ranged from 3.65 months for unspecified mutations to 21.29 for double EGFR mutations. Median PFS ranged from 1.77 months for unspecified mutations to 20.83 months for concomitant EGFR-anaplastic lymphoma kinase alteration. ORR varied from 0% in exon 18, 20 and double gene alteration to 66.6% in exon 19.Conclusion
Our study supports the existence of a strong outcome heterogeneity within patients harboring uncommon EGFR mutations, which needs to be clarified to achieve a real personalized treatment strategy. 相似文献89.
90.
Increased titers of IgG anti-GM1 and anti-asialo GM1 (GA1) ganglioside antibodies are present in some patients with the Guillain-Barré syndrome, particularly with the motor axonal variant, and following infection with Campylobacter jejuni or parenteral administration of gangliosides. The subclass distribution of IgG anti-GM1 or GA1 antibodies from 19 patients with acute motor neuropathy and elevated antibody titers were measured by ELISA using mouse monoclonal antibodies specific for human IgG subclasses. The anti-GM1 or GA1 antibodies were predominantly of the IgG1 and IgG3 subclasses, which are capable of complement fixation, and are characteristic of a T cell-dependent antibody response. 相似文献